News Release. Full-year net revenue increased Abraxis BioScience, Inc. The following table shows adjusted net income and adjusted net income per share for andwhich exclude intangible amortization and other costs related to the April merger between American Pharmaceutical Partners, Inc. Adjusted net income in excludes in process research and development.

Adjusted net income millions. Adjusted net income per share. Reconciliation tables appear below. Net revenue in the fourth quarter of increased This increase was primarily due to increases in sales commissions related to higher ABRAXANE revenues and shared marketing costs associated with the co-promotion agreement, and stock-based compensation. The company expects to have five Phase III trials active or initiated in Melanoma : The company Web Design And Seo Company India the FDA have agreed upon the Alley Supply Company and endpoints for the Phase III melanoma trial, which is expected to begin in the second half of The company plans to initiate the Phase III trials in pancreatic cancer by the end of Clinical studies began in the fourth quarter of The company recently announced that its partner, Taiho Pharmaceutical Co.

The submission in Japan includes four clinical studies that were part of the original New Drug Application in the United States. The company anticipates approval in Korea and China in the second quarter ofand in Russia and Australia in late The studies to be presented include the use of ABRAXANE as mono-therapy and in combination therapy in breast cancer and other tumor types, including melanoma, pancreatic, prostate and ovarian.

Global Development Team. In April, Abraxis formed a joint venture with Cenomed, Inc. This venture is designed to further the research and development of novel drugs that interact with the central nervous system focused on psychiatric and neurological diseases. In May, Abraxis entered into an agreement with the University of Southern California USC that provides the company with the exclusive worldwide development and commercialization rights for an Your Wedding Company Coupon Code property portfolio of diagnostic protein biomarkers for therapy response, therapy toxicity and disease recurrence in colorectal cancers CRCs.

In July, Abraxis entered into a research collaboration agreement Abraxane Company the California NanoSystems Institute, or CNSI, at UCLA under which the parties agreed to collaborate on early research in nanobiotechnology for the advancement of new technologies in medicine. This partnership provides Abraxis and CNSI researchers the opportunity to jointly pursue innovative approaches to the diagnosis and treatment of life-threatening diseases, leveraging the complementary resources and expertise of both organizations.

In July, Abraxis entered into an agreement with the Buck Institute for Age Research whereby the company exclusively licensed worldwide intellectual property rights for technologies designed to generate novel therapeutics and identify drug discovery targets. This fully-equipped facility, comprising approximatelysquare feet, includes manufacturing as well as chemistry and microbiology laboratories and has the ability to manufacture lyophilized powders, suspension products, and aqueous and Yoakum Packing Company solutions.

In July, Abraxis entered into an agreement with Biocon Limited under which it licensed the right to develop and commercialize a biosimilar version of G-CSF granulocyte-colony stimulating factor in North America and the European Union. Commercial introduction in the Indian market is expected in following completion of appropriate importation certifications. In addition, Green Cross granted an exclusive license to Abraxis for the commercialization of the following biosimilars in the U.

The accompanying consolidated and combined financial statements reflect the consolidated operations of Abraxis BioScience, Inc. To the extent that an asset, liability, revenue or expense is directly associated with the company, it is reflected in the accompanying consolidated and combined financial statements. Certain general corporate overhead and other expenses for periods prior to the separation have been allocated to the company.

Conference Call Information. The conference call may be heard by interested parties through a live audio Internet broadcast at www. For those unable to listen to the live broadcast, a playback of the webcast will be available at both websites for approximately six months beginning shortly after the conclusion of the call. The company believes that its Great Lakes Sign Company of non-GAAP financial measures, such as adjusted net income and adjusted net income per share, provide useful supplementary information to investors in understanding the underlying operating performance of the company and facilitates additional analysis by investors.

The company also uses Abraxane Company financial measures internally for operating, budgeting and financial planning purposes. The non-GAAP financial measures presented by the company may not be comparable to similarly titled measures reported by other companies. The non-GAAP financial measures are in addition to, and not a substitute for or superior to, measures of financial performance calculated in accordance with GAAP.

The U. Prior therapy should have included an anthracycline unless clinically contraindicated. About Abraxis BioScience. Forward-looking statements in this press release include statements regarding our 100 Foreign Owned Company In Vietnam, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the clinical development plan, and the timing and scope of clinical studies and trials, for ABRAXANE and the approval and launch of ABRAXANE in Europe.

Investors and Media Inquiries:. Daniel Saks. Vice President. Investor Relations and Corporate Communications. Abraxane Company and Combined Statements of Operation 1. In thousands, except share and per share amounts. Abraxane revenue. Other revenue. Net revenue. Cost of sales. Gross profit. Percent to net revenue. Operating expenses. Research and development.

Selling, general and administrative. Amortization of merger related intangibles. Merger-related in-process research and development charge. Other merger related costs. Equity in net income of Drug Source Co. Total operating expenses. Loss from operations. Interest income and other. Interest expense. Loss before income taxes. Provision benefit for income taxes. Net loss. Basic and diluted loss per share:. Weighted-average basic and diluted common shares outstanding: 2.

The composition of stock-based compensation included above is as follows:. Total stock-based compensation. The same number of shares is being used for both diluted earnings per share and basic earnings per share for all periods prior to the separation date. All potentially dilutive equity stock awards were excluded from the computation of diluted loss per common share for all periods as the effect on net loss per share was anti-dilutive.

Adjusted net income and adjusted net income per share are defined as net income and net income per share, respectively, in each case excluding the impact of merger-related costs, in-process research and development charges, non-cash stock compensation expense, amortization of acquired intangible assets, and Phoenix pre-launch costs. We believe that our presentation of non-GAAP financial measures provide useful supplementary information to investors in understanding our underlying operating performance and facilitates additional analysis by investors.

We also use non-GAAP financial measures internally for operating, budgeting and financing planning purposes. Reconciliation of net income and net income per share to adjusted net income and adjusted net income per share for each of the three and twelve months ended December 31, and is below:. Merger Abraxane Company items. Intangible amortization. In-process research and development charge. Total merger related costs. Phoenix pre-launch costs.

Stock compensation expense. Adjusted net income. Weighted-average common shares outstanding:. Basic and diluted. Net loss per share. Net loss before income tax. Pretax merger related items. Total pretax merger related costs. Adjusted net income before income tax. Consolidated and Combined Condensed Balance Sheets. Current assets:. Cash and cash equivalents.

Accounts receivable, net of chargebacks. Prepaid expenses and other current assets. Deferred income taxes.

Protein-bound paclitaxel - Wikipedia

Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others.Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division. In this formulation, paclitaxel is bonded to albumin as a delivery vehicle.Paclitaxel: Mitotic inhibitor…

SECTION 1 - IDENTIFICATION OF THE SUBSTANCE/MIXTURE …

SECTION 1 - IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/ UNDERTAKING Contact information General Celgene Pty Ltd Level 15, 60 City Road, Southbank, VIC 3006 ... Abraxane ® contains paclitaxel, a cytotoxic antineoplastic agent. Medical conditions aggravated by exposure: None known or reported. Treat symptomatically and…